摘要
目的：探讨重组人白介素-11(rhIL-11)衍生物在治疗恶性肿瘤患者化疗后血小板减少的临床应用效果。方法：2012年1月-2014年1月收治恶性肿瘤患者40例，采用自身对照试验，分为2个周期，第1个治疗周期化疗后不加用rhIL-11，第2个周期化疗后24～48h内加用rhIL-11治疗，比较两组血小板减少情况。结果：40例患者在第2个周期时的血小板计数最低值明显高于第1个周期(P＜0.05)，血小板计数≤50×109/L的持续时间明显小于第1个周期(P＜0.05)，血小板恢复至正常值的时间明显短于第1个周期(P＜0.05)，输注血小板的发生率明显小于第1个周期(P＜0.05)，所有患者第2个周期无出血发生，且不良反应轻微。结论：rhIL-11衍生物在预防恶性肿瘤患者化疗后血小板减少中的作用显著，且不良反应轻微，值得推广应用。
Objective:To investigate the effect of thrombocytopenia in patients with malignant tumor who were treated with recombinant human interleukin-11 derivatives.Methods:40 patients with malignant tumor were selected from January 2012 to January 2014.With a self control,this study divided into 2 periods,in the first treatment cycles,did not given rhIL-11 after chemotherapy,while in the second cycles,patients were given rhIL-11 within 24～48 h after chemotherapy,then we compared thrombocytopenic conditions in two groups.Results:In those 40 patients the lowest value of platelet count in the second cycle was significantly higher than that in the first period(P<0.05);the duration of platelet count less than 50 × 109/L was significantly shorter than the first cycles(P<0.05),and the time of platelet recovery to normal value also was obviously shorter than the first cycles(P<0.05);the incidence of platelet transfusion was significantly less than the first cycles(P<0.05);none of the patients occurred hemorrhage in second cycles,and the adverse reaction was mild.Conclusion:RhIL-11 derivatives used in patients with malignant tumor has significantly effect on prevention of thrombocytopenia after chemotherapy,and the adverse reactions is mild,so it is worthy of popularization and application.
作者
陈艳琼
Chen Yanqiong(First People's Hospital of Qujing City,Yunnan Province 655000)
出处
《中国社区医师》
2015年第13期64-65,共2页
Chinese Community Doctors
关键词
恶性肿瘤
化疗
血小板减少
重组人白介素-11衍生物
Malignant tumor
Chemotherapy
Thrombocytopenia
Recombinant human interleukin -11 derivatives
